RXDX · Prometheus Biosciences, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2022 | FY 2021 |
|---|---|---|
| Revenue | $6.81M | $1.23M |
| Cost of Revenue | - | - |
| Gross Profit | - | - |
| R&D | $112.85M | $19.15M |
| SG&A | $39.74M | $11.09M |
| Total Operating Expenses | $152.59M | $30.24M |
| D&A | $629.0K | $109.0K |
| Operating Income | ($145.78M) | ($29.01M) |
| Interest Expense | - | $2.13M |
| Income Tax | $0 | - |
| Net Income | ($141.75M) | ($37.14M) |
| EPS - Basic | ($3.49) | ($24.78) |
| EPS - Diluted | ($24.78) | - |
Balance Sheet
| Line item | FY 2022 | FY 2021 |
|---|---|---|
| Cash & Equivalents | $292.42M | $257.25M |
| Accounts Receivable | $1.03M | $1.08M |
| Inventory | - | - |
| Accounts Payable | $762.0K | $1.15M |
| Current Assets | $708.15M | $265.38M |
| Total Assets | $740.77M | $267.80M |
| Current Liabilities | $22.82M | $16.44M |
| Long-term Debt | - | - |
| Total Liabilities | $64.81M | $32.65M |
| Stockholders' Equity | $675.97M | $235.16M |
| Retained Earnings | ($331.09M) | ($189.34M) |
Cash Flow
| Line item | FY 2022 | FY 2021 |
|---|---|---|
| Operating Cash Flow | ($123.25M) | ($28.02M) |
| Investing Cash Flow | ($403.78M) | ($1.06M) |
| Financing Cash Flow | $562.20M | $79.89M |
| CapEx | $2.70M | $204.0K |
| Free Cash Flow | ($125.96M) | ($28.22M) |
Ratios
| Metric | FY 2022 | FY 2021 |
|---|---|---|
| Profitability | ||
| Gross margin | - | - |
| Operating margin | -2141.0% | -2360.2% |
| EBITDA margin | -2131.7% | -2351.3% |
| Net margin | -2081.8% | -3021.8% |
| Free cash flow margin | -1849.9% | -2296.3% |
| FCF / Net income | 0.89 | 0.76 |
| R&D / Revenue | 1657.3% | 1557.9% |
| SG&A / Revenue | 583.6% | 902.3% |
| Effective tax rate | - | - |
| Return on assets | -19.1% | -13.9% |
| Return on equity | -21.0% | -15.8% |
| Return on invested capital | - | - |
| Liquidity | ||
| Current ratio | 31.04 | 16.14 |
| Quick ratio | 31.04 | 16.14 |
| Cash ratio | 12.82 | 15.65 |
| Leverage | ||
| Debt / Equity | - | - |
| Debt / Assets | - | - |
| Debt / EBITDA | - | - |
| Interest coverage | - | -13.6x |
| Equity multiplier | 1.10 | 1.14 |
| Liabilities / Assets | 0.09 | 0.12 |
| Efficiency | ||
| Asset turnover | 0.01 | 0.00 |
| Inventory turnover | - | - |
| Days sales outstanding | 55d | 320d |
| Days inventory outstanding | - | - |
| Days payable outstanding | - | - |
| Cash conversion cycle | - | - |
| Valuation | ||
| P / E | - | - |
| P / B | - | - |
| P / S | - | - |
| EV / EBITDA | - | - |
| Growth | ||
| Revenue growth (YoY) | 454.0% | - |
| Revenue CAGR (3y) | - | - |
| Revenue CAGR (5y) | - | - |
| Gross profit growth (YoY) | - | - |
| Operating income growth (YoY) | -402.6% | - |
| Net income growth (YoY) | -281.7% | - |
| EPS growth (YoY) | - | - |
| EPS CAGR (3y) | - | - |
| EPS CAGR (5y) | - | - |
| FCF growth (YoY) | -346.3% | - |
| FCF CAGR (5y) | - | - |
| Book value growth (YoY) | 187.5% | - |
Stability scores
Altman Z′
FY 2022 · bankruptcy risk
4.06
Safe
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2022 · 9-point quality
3/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- -No share dilution
- -Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Prometheus Biosciences against the 5 most active filers in the same SIC group.